Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 85
- Registration Number
- NCT03301857
- Locations
- 🇺🇸
Sarcoma Oncology Research Center LLC, Santa Monica, California, United States
🇺🇸Mount Sinai Beth Israel Downtown, New York, New York, United States
🇺🇸University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 190
- Registration Number
- NCT03293108
- Locations
- 🇮🇷
Rheumatology Center of Iran, Tehran, Iran, Islamic Republic of
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Hebei Medical University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03259152
- Locations
- 🇨🇳
Zhuang Zhou, Shijiazhuang, Hebei, China
Effect of Denosumab in Erosion Healing in RA
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 110
- Registration Number
- NCT03239080
- Locations
- 🇨🇳
Department of Medicine and Therapeutics, Hong Kong, China
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Western University of Health Sciences
- Target Recruit Count
- 7
- Registration Number
- NCT03174366
- Locations
- 🇺🇸
Western University of Health Sciences, Pomona, California, United States
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT03164928
- Locations
- 🇦🇺
Perth Childrens Hospital, Nedlands, Western Australia, Australia
🇷🇺FSAI Scientific Center of Childrens Health of MoH of the RF, Moscow, Russian Federation
🇹🇷Ankara Universitesi Tip Fakultesi, Ankara, Turkey
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 72
- Registration Number
- NCT03161756
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Denosumab and Male Infertility: a RCT
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Martin Blomberg Jensen
- Target Recruit Count
- 95
- Registration Number
- NCT03030196
- Locations
- 🇩🇰
Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark
Denosumab Versus Bisphosphonates (Alendronate) in GIOP
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03005678
- Locations
- 🇨🇳
Department of Medicine, Tuen Mun Hospital, Hong Kong, China
Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 20
- Registration Number
- NCT02903446
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.